Aptose Biosciences Inc. Announces Board and Officer Changes

Ticker: APTOF · Form: 8-K · Filed: Aug 27, 2025 · CIK: 882361

Sentiment: neutral

Topics: management-change, board-of-directors, officer-appointment

TL;DR

Board shakeup at Aptose Biosciences Inc. - new directors in, some execs out.

AI Summary

Aptose Biosciences Inc. announced on August 19, 2025, changes related to its board of directors and officers. The filing details the departure of certain directors and officers, the election of new directors, and updates regarding compensatory arrangements for its officers. Specific details on the individuals involved and the financial implications of these changes are outlined in the report.

Why It Matters

Changes in board and officer composition can signal shifts in company strategy, governance, or operational focus, potentially impacting investor confidence and future performance.

Risk Assessment

Risk Level: medium — Changes in leadership and officer roles can introduce uncertainty regarding future strategy and execution.

Key Players & Entities

FAQ

What specific roles have been affected by the departure of directors or officers?

The filing indicates the departure of certain directors or officers, and the election of new directors, but does not specify the exact roles vacated or filled in this summary.

When was the earliest event reported in this 8-K filing?

The earliest event reported was on August 19, 2025.

What is the SEC file number for Aptose Biosciences Inc.?

The SEC file number for Aptose Biosciences Inc. is 001-32001.

What is the primary business of Aptose Biosciences Inc.?

Aptose Biosciences Inc. is in the business of Biological Products (No Diagnostic Substances).

What is the fiscal year end for Aptose Biosciences Inc.?

The fiscal year end for Aptose Biosciences Inc. is December 31.

Filing Stats: 570 words · 2 min read · ~2 pages · Grade level 11.1 · Accepted 2025-08-27 17:00:17

Key Financial Figures

Filing Documents

From the Filing

8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 19, 2025 APTOSE BIOSCIENCES INC. (Exact name of registrant as specified in its charter) Canada 001-32001 98-1136802 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.R.S. Employer Identification No.) 66 Wellington Street West , Suite 5300 TD Bank Tower, Box 48 Toronto , Ontario M5K 1E6 Canada (Address of Principal Executive Offices) (Zip Code) (647) 479-9828 (Registrant's telephone number, including area code) (Former name or former address, if changed since last report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered N/A N/A N/A Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (240.12b-2 of this chapter). Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Item5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers On August 19, 2025, in order to reward, retain and further incentivize certain members of the leadership team of Aptose Biosciences Inc (the "Company") and to continue to maintain a strong emphasis on long-term shareholder value creation, the Company entered into retention award agreements (the "Retention Award Agreement") for each of (i) William Rice, Chief Executive Officer of the Company, and (ii) Fletcher Payne, Senior Vice President, Chief Financial Officer of the Company and (iii) Rafael Bejar, Senior Vice President, Chief Medical Officer of the Company, respectively (each, a "Retention Grant"). Each Retention Grant, consists of a cash payment to be paid within five (5) days upon the closing of a "Change of Control" as defined in each Retention Award Agreement. Capitalized terms used but not defined herein shall have the meanings ascribed to them in the Retention Agreement. The Retention Grant for Dr. Rice was $331,496.00, the Retention Grant for Mr. Payne was $167,058.67 and the Retention Grant for Dr. Bejar was $199,946.67. The Retention Agreements provide that if the executive officer is not "Actively Employed" as defined in the Retention Agreement at the time of the closing of a "Change of Control" then the Retention Grant will not be paid. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Aptose Biosciences Inc. Date: August 27, 2025 By: /s/ William G. Rice William G. Rice, Ph.D. President and Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing